Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06745024 · ClinicalTrials.gov registry record · Phase 3

Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial

A Phase 3 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Bone, sponsored by NRG Oncology.

Recruiting
Registry status
Phase 3
Development phase
280
Enrollment target
20
Study locations

NCT06745024 is a Phase 3 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Bone that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 280 participants, above the 203-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06745024, a Phase 3 study of Metastatic Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Bone, is actively recruiting participants, sponsored by NRG Oncology.

RECRUITING
Registry status
Phase 3
Development phase
280 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pain warranting surgery or radiation treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The total dose of radiation can be delivered in a single day or divided in smaller doses for up to 5 days of total treatment. Usual care for asymptomatic bone metastases may include drugs that prevent bone loss, in addition to the treatment for the primary cancer or observation (which means no treatment until symptoms appear). Evidence has shown that preventative radiation therapy may be effective in lowering the number of bone metastases-related complications, however, it is not known if this approach is superior to usual care. Adding radiation therapy to usual care may be more effective in preventing bone-related complications than usual care alone in cancer patients with asymptomatic high-risk bone metastases.

Conditions Studied

Metastatic Malignant Solid Neoplasm Metastatic Malignant Neoplasm in the Bone

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • OTHER Best Practice
  • OTHER Bone Metastases Treatment
  • PROCEDURE Conventional Radiotherapy

Study Locations (20)

California

  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
  • Sutter Auburn Faith Hospital - Auburn
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
  • Alta Bates Summit Medical Center-Herrick Campus - Berkeley
  • Mills-Peninsula Medical Center - Burlingame
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
  • Mercy Cancer Center - Carmichael - Carmichael
  • Mercy San Juan Medical Center - Carmichael
  • Eden Hospital Medical Center - Castro Valley
  • Kaiser Permanente Dublin - Dublin
  • Mercy Cancer Center - Elk Grove - Elk Grove
  • UC San Diego Health System - Encinitas - Encinitas

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Cancer Center at Saint Joseph's - Phoenix
  • Banner-University Medical Center Phoenix - Phoenix
  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Alaska

  • Fairbanks Memorial Hospital - Fairbanks

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2025-04-14
Est. Completion 2029-02-01
Phase Phase 3

Sponsor

NRG Oncology

64 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06745024

The ClinicalTrials.gov registry entry for NCT06745024 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (38% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06745024 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alaska.

Frequently Asked Questions

What is clinical trial NCT06745024 about?

NCT06745024 is a clinical study titled "Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial". This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, s...

What is the current status of trial NCT06745024?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2025-04-14. Estimated completion is 2029-02-01.

What conditions does trial NCT06745024 study?

This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone.

What interventions are being tested in trial NCT06745024?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Best Practice (OTHER), Bone Metastases Treatment (OTHER), Conventional Radiotherapy (PROCEDURE).

Who is sponsoring clinical trial NCT06745024?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06745024 being conducted?

This trial has 20 study locations across Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Malignant Solid Neoplasm

All registered trials for this condition

Metastatic Malignant Neoplasm in the Bone

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.